ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Horizon Pharma plc (HZNP) Report Updated: Oct 19, 2014 | Print This Page

Get more stock ratings by Louis Navellier

Horizon Pharma plc (HZNP)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Pharmaceuticals
Competitors: IMMY, LCI, AKRX, ANIP

Stock Analysis

Rating: Monthly View

A
B
C
D
F
October November December January February March April May June July August September

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

Horizon Pharma plc© quotemedia

Company Profile

Horizon Pharma, Inc., a biopharmaceutical company, through its subsidiaries, develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. The company offers DUEXIS for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications; and LODOTRA/RAYOS for the treatment of moderate to severe active rheumatoid arthritis in adults when accompanied by morning stiffness. It also develops LODOTRA/RAYOS, which is under Phase 2 clinical trial for the treatment of polymyalgia rheumatica. The company was founded in 2005 and is headquartered in Deerfield, Illinois.

Recent News: Horizon Pharma plc